N-arachidonoyl glycine, an endogenous lipid that acts as a vasorelaxant via nitric oxide and large conductance calcium-activated potassium channels

British Journal of Pharmacology

Volumn 160, Issue 3, 2010, Pages 594-603

  Parmar, Neelam ^a   Ho, W S Vanessa ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cannabinoid receptor; Endothelium; N arachidonoyl glycine; N arachidonoyl serine; N arachidonoyl aminobutyric acid; Nitric oxide; Potassium channels; Rat mesenteric artery; TRPV1 receptor

Indexed keywords

COCODAMOL; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; GLYCINE DERIVATIVE; INDOMETACIN; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; N ARACHIDONOYL GLYCINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; O 1919; PROSTAGLANDIN SYNTHASE; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; 4 AMINOBUTYRIC ACID; ARACHIDONIC ACID DERIVATIVE; GLYCINE; IBERIOTOXIN; N(G) NITROARGININE METHYL ESTER; N-ARACHIDONOYL L-SERINE; N-ARACHIDONOYL-GAMMA-AMINO-BUTYRIC ACID; N-ARACHIDONYLGLYCINE; PEPTIDE; PERTUSSIS TOXIN; SERINE;

ANIMAL TISSUE; ARTICLE; BLOOD VESSEL TONE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; GENE ACTIVATION; MALE; MYOGRAPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM; VASODILATATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG INTERACTION; MESENTERIC ARTERY; PHYSIOLOGY; WISTAR RAT;

ANIMALS; ARACHIDONIC ACIDS; DRUG INTERACTIONS; ENDOTHELIUM, VASCULAR; GAMMA-AMINOBUTYRIC ACID; GLYCINE; LARGE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; MALE; MESENTERIC ARTERIES; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; PEPTIDES; PERTUSSIS TOXIN; RATS; RATS, WISTAR; SERINE; VASODILATION;

EID: 77952609532     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00622.x     Document Type: Article

References (34)

1. Alexander SP, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edition. Br J Pharmacol 153 (Suppl. 2 S1 209.
2. + current. J Biol Chem 278 : 46188 46194.
3. Burstein SH (1999). The cannabinoid acids: nonpsychoactive derivatives with therapeutic potential. Pharmacol Ther 82 : 87 96.
4. Burstein SH, Rossetti RG, Yagen B, Zurier RB (2000). Oxidative metabolism of anandamide. Prostaglandins Other Lipid Mediat 61 : 29 41.
5. Burstein SH, Huang SM, Petros TJ, Rossetti RG, Walker JM, Zurier RB (2002). Regulation of anandamide tissue levels by N-arachidonylglycine. Biochem Pharmacol 64 : 1147 1150.
6. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384 : 83 87.
7. Deutsch D, Goligorsky MS, Schmid PC, Krebsbach RJ, Schmid HHO, Das SK et al. (1997). Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest 100 : 1538 1546.
8. Galvez A, Gimenez-Gallego G, Reuben JP, Roy-Contancin L, Feigenbaum P, Kaczorowski GJ et al. (1990). Purification and characterization of a unique, potent, peptidyl probe for the high conductance calcium-activated potassium channel from venom of the scorpion Buthus tamulus. J Biol Chem 265 : 11083 11090.
9. 2+ channel current. Am J Physiol 276 : H2085 H2093.
10. + channels. J Pharmacol Exp Ther 328 : 351 361.
11. Gunthorpe MJ, Rami HK, Jerman JC, Smart D, Gill CH, Soffin EM et al. (2004). Identification and characterisation of SB-366791, a potent and selective vanilloid receptor (VR1/TRPV1) antagonist. Neuropharmacology 46 : 133 149.
12. Ho WS, Gardiner SM (2009). Acute hypertension reveals depressor and vasodilator effects of cannabinoids in conscious rats. Br J Pharmacol 156 : 94 104.
13. Ho WS, Hiley CR (2003). Vasodilator actions of abnormal-cannabidiol in rat isolated small mesenteric artery. Br J Pharmacol 138 : 1320 1332.
14. Ho WS, Randall MD (2007). Endothelium-dependent metabolism by endocannabinoid hydrolases and cyclooxygenases limits vasorelaxation to anandamide and 2-arachidonoylglycerol. Br J Pharmacol 150 : 641 651.
15. Ho WS, Barrett DA, Randall MD (2008). 'Entourage' effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. Br J Pharmacol 155 : 837 846.
16. Huang SM, Bisogno T, Petros TJ, Chang SY, Zavitsanos PA, Zipkin RE et al. (2001). Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. J Biol Chem 276 : 42639 42644.
17. Iwamura H, Suzuki H, Ueda Y, Kaya T, Inaba T (2001). In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. J Pharmacol Exp Ther 296 : 420 425.
18. Jarai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR et al. (1999). Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA 96 : 14136 14141.
19. Johns DG, Behm DJ, Walker DJ, Ao Z, Shapland EM, Daniels DA et al. (2007). The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol 152 : 825 831.
20. Lan R, Liu Q, Fan P, Fernando SR, McCallion D, Pertwee R et al. (1999). Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem 25 : 769 776.
21. Ledoux J, Werner ME, Brayden JE, Nelson MT (2006). Calcium-activated potassium channels and the regulation of vascular tone. Physiology (Bethesda) 21 : 69 78.
22. McCollum L, Howlett AC, Mukhopadhyay S (2007). Anandamide-mediated CB1/CB2 cannabinoid receptor - independent nitric oxide production in rabbit aortic endothelial cells. J Pharmacol Exp Ther 321 : 930 937.
23. Milman G, Maor Y, Abu-Lafi S, Horowitz M, Gallily R, Batkai S et al. (2006). N-arachidonoyl l-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proc Natl Acad Sci USA 103 : 2428 2433.
24. + channels (BK(Ca)) in smooth muscle cells isolated from the rat mesenteric artery. Br J Pharmacol 124 : 1131 1140.
25. Mukhopadhyay S, Chapnick BM, Howlett AC (2002). Anandamide-induced vasorelaxation in rabbit aortic rings has two components: G protein dependent and independent. Am J Physiol Heart Circ Physiol 282 : H2046 H2054.
26. Offertaler L, Mo FM, Batkai S, Liu J, Begg M, Razdan RK et al. (2003). Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol 63 : 699 705.
27. O'Sullivan SE, Kendall DA, Randall MD (2004). Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-dopamine (NADA). Br J Pharmacol 141 : 803 812.
28. + channels in pulmonary vascular smooth muscle cells: role of nitric oxide. J Appl Physiol 81 : 1264 1272.
29. Prusakiewicz JJ, Kingsley PJ, Kozak KR, Marnett LJ (2002). Selective oxygenation of N-arachidonylglycine by cyclooxygenase-2. Biochem Biophys Res Commun 296 : 612 617.
30. Romano MR, Lograno MD (2006). Cannabinoid agonists induce relaxation in the bovine ophthalmic artery: evidences for CB1 receptors, nitric oxide and potassium channels. Br J Pharmacol 147 : 917 925.
31. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J et al. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152 : 1092 1101.
32. Sheskin T, Hanus L, Slager J, Vogel Z, Mechoulam R (1997). Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J Med Chem 40 : 659 667.
33. White R, Ho WS, Bottrill FE, Ford WR, Hiley CR (2001). Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries. Br J Pharmacol 134 : 921 929.
34. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V et al. (1999). Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400 : 452 457.